SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions.
$36.95+8.41%
报价 2026-11-06
市值
$1.24B
EV
$515.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 0.0%
$17.56$36.95
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SGPSpyGlass Pharma, Inc. Common Stock | $1.24B | +8.4% | – | 0% | – | – | – | |
| GHRSGH Research PLC | $1.28B | +0.9% | – | 0% | – | – | – | |
| DRTSAlpha Tau Medical Ltd. | $1.27B | +3.2% | – | 0% | – | – | – | |
| TYRATyra Biosciences, Inc. | $1.26B | +1.2% | – | 0% | – | – | – | |
| MNKDMannKind Corporation | $1.25B | +3.7% | +28.5% | 75.7% | – | 49.6x | – | |
| INBXInhibrx Biosciences, Inc. | $1.24B | +5.3% | +230.8% | 0% | – | – | – | |
| OMEROmeros Corporation | $1.22B | -0.9% | +2728.0% | 95.8% | 9.7x | 10.7x | – | |
| URGNUroGen Pharma Ltd. | $1.21B | -3.8% | +135.3% | 90.9% | – | – | – | |
| RAPPRapport Therapeutics, Inc. Common Stock | $1.17B | +3.0% | 0.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +135.3% | 0% | 9.7x | 30.1x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。